{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:26:11Z","timestamp":1787498771483,"version":"build-2736575974"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,10]]},"DOI":"10.18632\/oncotarget.19831","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T19:48:11Z","timestamp":1501703291000},"page":"82689-82699","source":"Crossref","is-referenced-by-count":36,"title":["Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine"],"prefix":"10.18632","volume":"8","author":[{"given":"Jing","family":"Pan","sequence":"first","affiliation":[{"name":"Cancer Center and Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center and Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuko","family":"Sei","sequence":"additional","affiliation":[{"name":"Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Shoemaker","sequence":"additional","affiliation":[{"name":"Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Lubet","sequence":"additional","affiliation":[{"name":"Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center and Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"You","sequence":"additional","affiliation":[{"name":"Cancer Center and Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13238-014-0031-6","article-title":"Driver mutations of cancer epigenomes","volume":"5","author":"Chan","year":"2014","journal-title":"Protein Cell"},{"key":"3","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Kinzler","year":"2013","journal-title":"Science"},{"key":"4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/path.4275","article-title":"The evolving genomic classification of lung cancer","volume":"232","author":"Wistuba","year":"2014","journal-title":"J Pathol"},{"key":"5","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Mattos","year":"2012","journal-title":"Cancer Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Der","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Shokat","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrc1815","article-title":"Vaccines for tumour prevention","volume":"6","author":"Forni","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1940-6207.CAPR-13-0182","article-title":"A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease","volume":"6","author":"Lubet","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"10","first-page":"1517","article-title":"Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: Anstudy in a murine model of EGFR mutant lung cancer","volume":"55","author":"You","year":"2015","journal-title":"Mol Carcinog"},{"key":"11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cllc.2014.06.002","article-title":"Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation","volume":"15","author":"Azzoli","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1080\/21645515.2014.1004017","article-title":"Pancreatic cancer, treatment options, and GI-4000","volume":"10","author":"Marshall","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/13543784.2014.876408","article-title":"GI-4000 in KRAS mutant cancers","volume":"23","author":"O'Neil","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/21645515.2015.1011017","article-title":"Pancreatic cancer, treatment options, and GI-4000","volume":"11","author":"Marshall","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"15","doi-asserted-by":"crossref","first-page":"e86658","DOI":"10.1371\/journal.pone.0086658","article-title":"Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens","volume":"9","author":"Sala","year":"2014","journal-title":"PLoS One"},{"key":"16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/1940-6207.CAPR-14-0213","article-title":"Cancer immunoprevention: a new approach to intercept cancer early","volume":"7","author":"Umar","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"17","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.4049\/jimmunol.172.7.4215","article-title":"CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors","volume":"172","author":"Allen","year":"2004","journal-title":"J Immunol"},{"key":"18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00002371-199903000-00007","article-title":"A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors","volume":"22","author":"Schlom","year":"1999","journal-title":"J Immunother"},{"key":"19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00262-008-0477-6","article-title":"Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers","volume":"57","author":"Khleif","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"20","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1101\/gad.947701","article-title":"Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes","volume":"15","author":"Varmus","year":"2001","journal-title":"Genes Dev"},{"key":"21","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1158\/0008-5472.CAN-07-5891","article-title":"Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer","volume":"68","author":"Disis","year":"2008","journal-title":"Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2007.05.003","article-title":"An open-label, prospective phase I\/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer","volume":"58","author":"Buhl","year":"2007","journal-title":"Lung Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission Possible?","volume":"13","author":"Der","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H","article-title":"Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung","volume":"92","author":"Sidransky","year":"2001","journal-title":"Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/eji.1830260225","article-title":"Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses","volume":"26","author":"Schlom","year":"1996","journal-title":"Eur J Immunol"},{"key":"26","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.4049\/jimmunol.160.5.2433","article-title":"Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties","volume":"160","author":"Abrams","year":"1998","journal-title":"J Immunol"},{"key":"27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ijc.1205","article-title":"Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma","volume":"92","author":"Gaudernack","year":"2001","journal-title":"Int J Cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E","article-title":"ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I\/II study","volume":"65","author":"Gaudernack","year":"1996","journal-title":"Int J Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<784::AID-IJC14>3.0.CO;2-9","article-title":"Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation","volume":"72","author":"Gaudernack","year":"1997","journal-title":"Int J Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.2005.03.158","article-title":"Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome","volume":"23","author":"Carter","year":"2005","journal-title":"J Clin Oncol"},{"key":"31","doi-asserted-by":"crossref","first-page":"9245","DOI":"10.1128\/MCB.23.24.9245-9250.2003","article-title":"While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable","volume":"23","author":"Patek","year":"2003","journal-title":"Mol Cell Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.surg.2005.06.059","article-title":"Vaccination with a HER2\/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer","volume":"139","author":"Peoples","year":"2006","journal-title":"Surgery"},{"key":"33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/vaccines3030490","article-title":"Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine","volume":"3","author":"Adotevi","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2051-1426-2-23","article-title":"A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes","volume":"2","author":"Slingluff","year":"2014","journal-title":"J Immunother Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"14793","DOI":"10.1038\/srep14793","article-title":"Immunodominant epitope-specific Th1 but not Th17 responses mediate protection against Helicobacter pylori infection following UreB vaccination of BALB\/c mice","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"36","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-12-0896","article-title":"Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor","volume":"18","author":"Tartour","year":"2012","journal-title":"Clin Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.4049\/jimmunol.0901017","article-title":"Protumor vs antitumor functions of IL-17","volume":"183","author":"Saha","year":"2009","journal-title":"J Immunol"},{"key":"38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00281-009-0191-2","article-title":"Th17 cytokines and vaccine-induced immunity","volume":"32","author":"Khader","year":"2010","journal-title":"Semin Immunopathol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:11:57Z","timestamp":1750781517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":38,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017,10,10]]}},"alternative-id":["19831","29137294"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19831","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}